ASSESSING METASTASIS/RELAPSE IN SENTINEL LYMPH NODE DISSECTION MELANOMA PATIENTS

评估前哨淋巴结切除黑色素瘤患者的转移/复发

• 批准号: 6424520
• 负责人: Dave S B Hoon
• 金额: $ 79.41万
• 依托单位: SAINT JOHN'S CANCER INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-02-23 至 2001-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6424520
• 关键词: SDS polyacrylamide gel electrophoresis; biomarker; biopsy; blood chemistry; cancer registry /resource; clinical research; cryopreservation; diagnosis design /evaluation; genetic markers; high performance liquid chromatography; human subject; human therapy evaluation; human tissue; lymph nodes; lymphadenectomy; melanoma; metastasis; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neoplastic process; polymerase chain reaction; prognosis; southern blotting

The Program Project's focus os on the assessment of the efficacy of sentinel lymph node dissection (SLND) in high-risk AJCC Stage II patients enrolled in the multi-center trial (MSLT). Accurate identification and analysis of the sentinel node can improve disease staging and guide further treatment. However, better methods are needed for the detection of metastatic disease and prediction of relapse in early-stage patients. The melanoma lesion, sentinel lymph node and blood of patients undergoing SLND are valuable resource for assessing new molecular methodologies. The project will focus on developing new molecular approaches to improve detection of metastatic disease in blood and sentinel lymph nodes. Melanoma markers developed for RT-PCR and automated Souther blot analysis will be used to evaluate blood and sentinel lymph nodes. We will assess the clinical utility of these molecular markers for detection of subclinical disease and prediction of relapse using blood specimens from SLND patients. We will also use melanoma marker RT-PCR to detect metastasis in frozen and archival paraffin selection of sentinel lymph nodes. The main objective will be to improve detection of micrometastic disease in sentinel lymph nodes. The main objective will be to improve detection of micrometastatic disease in sentinel lymph nodes and recurrent subclinical disease in blood to determine their potential clinicopathological utility in disease staging and prognosis. A method has been developed to asses tumor- specific DNA markers in serum. These markers will be assessed as tumor progression indicators using prospective and archival serum. The objective will be to identify patients with high potential for developing aggressive disease. The MSLT archival and prospective specimens along with their clinical follow up provide a unique resource to validate and determine clinical utility of these new molecular approaches.

该计划项目的重点OS对评估的功效评估 高危AJCC II期患者的前哨淋巴结清扫术（SLND） 参加了多中心试验（MSLT）。准确的识别和 哨兵节点的分析可以改善疾病分期和指导 进一步治疗。但是，需要更好的方法来检测 转移性疾病和早期患者复发的预测。这 黑色素瘤病变，哨兵淋巴结和接受SLND患者的血液 是评估新分子方法论的宝贵资源。 该项目将着重于开发新的分子方法来改进 检测血液和哨兵淋巴结中的转移性疾病。 为RT-PCR和自动化的Souther印迹分析而开发的黑色素瘤标志物 将用于评估血液和哨兵淋巴结。我们将评估 这些分子标记的临床实用性用于检测 亚临床疾病和使用血液标本的复发预测 SLND患者。我们还将使用黑色素瘤标记RT-PCR检测 Sentinel淋巴的冷冻和档案石蜡选择的转移 节点。主要目的是改善微观检测 哨兵淋巴结中的疾病。主要目标是改善 哨兵淋巴结和复发性的微转移疾病检测 血液中的亚临床疾病以确定其潜力 疾病分期和预后中的临床病理效用。一种方法 开发为血清中的肿瘤特异性DNA标记。这些 标记将使用前瞻性评估为肿瘤进展指标 和档案血清。目的是确定患者 发展侵略性疾病的潜力。 MSLT档案和 潜在标本及其临床随访提供了独特的 验证和确定这些新分子的临床实用性的资源 方法。